Search

Your search keyword '"Suker, Mustafa"' showing total 147 results
Start Over Author "Suker, Mustafa"
147 results on '"Suker, Mustafa"'

1. Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer

Author

Strijker, Marin, van der Sijde, Fleur, Suker, Mustafa, Boermeester, Marja A., Bonsing, Bert A., Bruno, Marco J., Busch, Olivier R., Doukas, Michail, van Eijck, Casper H., Gerritsen, Arja, Groot Koerkamp, Bas, Haj Mohammad, Nadia, van Hilst, Jony, de Hingh, Ignace H., van Hooft, Jeanin E., Luyer, Misha D., Quintus Molenaar, I., Verheij, Joanne, Waasdorp, Cynthia, Wilmink, Johanna W., Besselink, Marc G., van Laarhoven, Hanneke W., and Bijlsma, Maarten F.

Published
2021
Full Text
View/download PDF

2. External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer: Outcome of Eligible but Nonrandomized Patients

Author

Versteijne, Eva, Suker, Mustafa, Groen, Jesse V., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Busch, Olivier R., de Hingh, Ignace H. J. T., de Jong, Koert P., Molenaar, I. Quintus, van Santvoort, Hjalmar C., Verkooijen, Helena M., Van Eijck, Casper H., and van Tienhoven, Geertjan

Published
2022
Full Text
View/download PDF

3. Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial)

Author

van Dongen, Jelle C., Suker, Mustafa, Versteijne, Eva, Bonsing, Bert A., Mieog, J. Sven D., de Vos-Geelen, Judith, van der Harst, Erwin, Patijn, Gijs A., de Hingh, Ignace H., Festen, Sebastiaan, Ten Tije, Albert J., Busch, Olivier R., Besselink, Marc G., van Tienhoven, Geertjan, Koerkamp, Bas Groot, and van Eijck, Casper H. J.

Published
2022
Full Text
View/download PDF

5. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial

Author

Van Hilst, Jony, De Rooij, Thijs, Bosscha, Koop, Brinkman, David J, Van Dieren, Susan, Dijkgraaf, Marcel G, Gerhards, Michael F, De Hingh, Ignace H, Karsten, Tom M, Lips, Daniel J, Luyer, Misha D, Busch, Olivier R, Festen, Sebastiaan, Besselink, Marc G, Marsman, Hendrik A, Van Gulik, Thomas M, Wicherts, Dennis A, Eshuis, Wietse J, Stibbe, Luna A, Nieveen van Dijkum, Els JM, Van Hooft, Janine E, Fockens, Paul, Van Laarhoven, Hanneke W, Wilmink, Johanna W, Van de Vijver, Marcel J, Bijlsma, Maarten F, Verheij, Joanne, Nio, C Yung, Van Lienden, Krijn P, Van Tienhoven, Geertjan, Schoorlemmer, Annuska, Creemers, Geert-Jan, Van Eijck, Casper HJ, Groot Koerkamp, Bas, Bruno, Marco J, Eskens, Ferry, Nuyttens, Joost J, Pek, Chulja, Van der Schelling, George P, Seerden, Tom C, Patijn, Gijs A, Nieuwenhuijs, Vincent B, De Groot, Jan W, Bonsing, Bert A, Vahrmeijer, Alexander, Swijnenburg, Rutger J, Mieog, J Sven D, Van der Harst, Erwin, Den Dulk, Marcel, Olde Damink, Steven, Dejong, Cees HC, Van Dam, Ronald, De Vos, Judith MPGM, Liem, Mike SL, Van Laarhoven, Cees JHM, Van Goor, Harry, Van den Boezem, Peter B, Van der Kolk, B Marion, Stommel, Martijn WJ, Hermans, John J, Van Geenen, Erwin JM, Radema, Sandra A, Brosens, Lodewijk A, Scheepers, Joris JG, Roos, Daphne, Boerma, Djamilla, Te Riele, Wouter, Van Santvoort, Hjalmar C, Bollen, Thomas L, Wit, Fanny, Molenaar, I Quintus, Haj Mohammad, Nadia, Van Leeuwen, Maarten S, Roele, Annemarie, De Jong, Kees P, De Meijer, Vincent E, Klaase, Joost M, Kazemier, Geert, Zonderhuis, Babs, Daams, Freek, Meijerink, Martijn R, Latenstein, Anouk, Van Rijssen, L Bengt, Nota, Carolijn, Van Halsema, Emo, Van Veldhuisen, Eran, Vogel, Jantien, Janssen, Kiki, Scholten, Lianne, Daamen, Lois, Walma, Marieke, Strijker, Marin, Prins, Mariska, Zwart, Maurice, Suker, Mustafa, Rombouts, Steffi, Mungroop, Timothy, Vissers, Frederique, Korrel, Maarten, van Hilst, Jony, de Rooij, Thijs, van Dieren, Susan, and de Hingh, Ignace H

Published
2019
Full Text
View/download PDF

6. Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial)

Author

van Dongen, Jelle C., Suker, Mustafa, Versteijne, Eva, Bonsing, Bert A., Mieog, J. Sven D., de Vos-Geelen, Judith, van der Harst, Erwin, Patijn, Gijs A., de Hingh, Ignace H., Festen, Sebastiaan, Ten Tije, Albert J., Busch, Olivier R., Besselink, Marc G., van Tienhoven, Geertjan, Groot Koerkamp, Bas, and van Eijck, Casper H. J.

Published
2020
Full Text
View/download PDF

9. Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD): A Multicenter Patient-blinded Randomized Controlled Trial

Author

de Rooij, Thijs, van Hilst, Jony, van Santvoort, Hjalmar, Boerma, Djamila, van den Boezem, Peter, Daams, Freek, van Dam, Ronald, Dejong, Cees, van Duyn, Eino, Dijkgraaf, Marcel, van Eijck, Casper, Festen, Sebastiaan, Gerhards, Michael, Groot Koerkamp, Bas, de Hingh, Ignace, Kazemier, Geert, Klaase, Joost, de Kleine, Ruben, van Laarhoven, Cornelis, Luyer, Misha, Patijn, Gijs, Steenvoorde, Pascal, Suker, Mustafa, Abu Hilal, Moh’d, Busch, Olivier, and Besselink, Marc

Published
2018
Full Text
View/download PDF

10. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials

Author

Doppenberg, Deesje, van Dam, Jacob L., Han, Youngmin, Bonsing, Bert A., Busch, Olivier R., Festen, Sebastiaan, van der Harst, Erwin, de Hingh, Ignace H., Homs, Marjolein Y.V., Kwon, Wooil, Lee, Mirang, Lips, Daan J., de Meijer, Vincent E., Molenaar, I. Quintus, Nuyttens, Joost J., Patijn, Gijs A., van Roessel, Stijn, van der Schelling, George P., Suker, Mustafa, Versteijne, Eva, de Vos-Geelen, Judith, Wilmink, Johanna W., van Eijck, Casper H.J., van Tienhoven, Geertjan, Jang, Jin Young, Besselink, Marc G., Groot Koerkamp, Bas, Doppenberg, Deesje, van Dam, Jacob L., Han, Youngmin, Bonsing, Bert A., Busch, Olivier R., Festen, Sebastiaan, van der Harst, Erwin, de Hingh, Ignace H., Homs, Marjolein Y.V., Kwon, Wooil, Lee, Mirang, Lips, Daan J., de Meijer, Vincent E., Molenaar, I. Quintus, Nuyttens, Joost J., Patijn, Gijs A., van Roessel, Stijn, van der Schelling, George P., Suker, Mustafa, Versteijne, Eva, de Vos-Geelen, Judith, Wilmink, Johanna W., van Eijck, Casper H.J., van Tienhoven, Geertjan, Jang, Jin Young, Besselink, Marc G., and Groot Koerkamp, Bas

Abstract

BACKGROUND: Guidelines suggest that the serum carbohydrate antigen (CA19-9) level should be used when deciding on neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (hereafter referred to as pancreatic cancer). In patients with resectable pancreatic cancer, neoadjuvant therapy is advised when the CA19-9 level is 'markedly elevated'. This study investigated the impact of baseline CA19-9 concentration on the treatment effect of neoadjuvant chemoradiotherapy (CRT) in patients with resectable and borderline resectable pancreatic cancers.METHODS: In this post hoc analysis, data were obtained from two RCTs that compared neoadjuvant CRT with upfront surgery in patients with resectable and borderline resectable pancreatic cancers. The effect of neoadjuvant treatment on overall survival was compared between patients with a serum CA19-9 level above or below 500 units/ml using the interaction test. RESULTS: Of 296 patients, 179 were eligible for analysis, 90 in the neoadjuvant CRT group and 89 in the upfront surgery group. Neoadjuvant CRT was associated with superior overall survival (HR 0.67, 95 per cent c.i. 0.48 to 0.94; P = 0.019). Among 127 patients (70, 9 per cent) with a low CA19-9 level, median overall survival was 23.5 months with neoadjuvant CRT and 16.3 months with upfront surgery (HR 0.63, 0.42 to 0.93). For 52 patients (29 per cent) with a high CA19-9 level, median overall survival was 15.5 months with neoadjuvant CRT and 12.9 months with upfront surgery (HR 0.82, 0.45 to 1.49). The interaction test for CA19-9 level exceeding 500 units/ml on the treatment effect of neoadjuvant CRT was not significant (P = 0.501). CONCLUSION: Baseline serum CA19-9 level defined as either high or low has prognostic value, but was not associated with the treatment effect of neoadjuvant CRT in patients with resectable and borderline resectable pancr

Published
2023

12. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial

Author

van Dongen, Jelle C., primary, Versteijne, Eva, additional, Bonsing, Bert A., additional, Mieog, J. Sven D., additional, de Hingh, Ignace H.J.T., additional, Festen, Sebastiaan, additional, Patijn, Gijs A., additional, van Dam, Ronald, additional, van der Harst, Erwin, additional, Wijsman, Jan H., additional, Bosscha, Koop, additional, van der Kolk, Marion, additional, de Meijer, Vincent E., additional, Liem, Mike S.L., additional, Busch, Olivier R., additional, Besselink, Marc G.H., additional, van Tienhoven, Geertjan, additional, Groot Koerkamp, Bas, additional, van Eijck, Casper H.J., additional, and Suker, Mustafa, additional

Published
2022
Full Text
View/download PDF

13. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer:Long-Term Results of the Dutch Randomized PREOPANC Trial

Author

Versteijne, Eva, van Dam, Jacob L, Suker, Mustafa, Janssen, Quisette P, Groothuis, Karin, Akkermans-Vogelaar, Janine M, Besselink, Marc G, Bonsing, Bert A, Buijsen, Jeroen, Busch, Olivier R, Creemers, Geert-Jan M, van Dam, Ronald M, Eskens, Ferry A L M, Festen, Sebastiaan, de Groot, Jan Willem B, Groot Koerkamp, Bas, de Hingh, Ignace H, Homs, Marjolein Y V, van Hooft, Jeanin E, Kerver, Emile D, Luelmo, Saskia A C, Neelis, Karen J, Nuyttens, Joost, Paardekooper, Gabriel M R M, Patijn, Gijs A, van der Sangen, Maurice J C, de Vos-Geelen, Judith, Wilmink, Johanna W, Zwinderman, Aeilko H, Punt, Cornelis J, van Tienhoven, Geertjan, van Eijck, Casper H J, Versteijne, Eva, van Dam, Jacob L, Suker, Mustafa, Janssen, Quisette P, Groothuis, Karin, Akkermans-Vogelaar, Janine M, Besselink, Marc G, Bonsing, Bert A, Buijsen, Jeroen, Busch, Olivier R, Creemers, Geert-Jan M, van Dam, Ronald M, Eskens, Ferry A L M, Festen, Sebastiaan, de Groot, Jan Willem B, Groot Koerkamp, Bas, de Hingh, Ignace H, Homs, Marjolein Y V, van Hooft, Jeanin E, Kerver, Emile D, Luelmo, Saskia A C, Neelis, Karen J, Nuyttens, Joost, Paardekooper, Gabriel M R M, Patijn, Gijs A, van der Sangen, Maurice J C, de Vos-Geelen, Judith, Wilmink, Johanna W, Zwinderman, Aeilko H, Punt, Cornelis J, van Tienhoven, Geertjan, and van Eijck, Casper H J

Abstract

PURPOSE: The benefit of neoadjuvant chemoradiotherapy in resectable and borderline resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial failed to demonstrate a statistically significant overall survival (OS) benefit. The long-term results are reported.METHODS: In this multicenter, phase III trial, patients with resectable and borderline resectable pancreatic cancer were randomly assigned (1:1) to neoadjuvant chemoradiotherapy or upfront surgery in 16 Dutch centers. Neoadjuvant chemoradiotherapy consisted of three cycles of gemcitabine combined with 36 Gy radiotherapy in 15 fractions during the second cycle. After restaging, patients underwent surgery followed by four cycles of adjuvant gemcitabine. Patients in the upfront surgery group underwent surgery followed by six cycles of adjuvant gemcitabine. The primary outcome was OS by intention-to-treat. No safety data were collected beyond the initial report of the trial.RESULTS: Between April 24, 2013, and July 25, 2017, 246 eligible patients were randomly assigned to neoadjuvant chemoradiotherapy (n = 119) and upfront surgery (n = 127). At a median follow-up of 59 months, the OS was better in the neoadjuvant chemoradiotherapy group than in the upfront surgery group (hazard ratio, 0.73; 95% CI, 0.56 to 0.96; P = .025). Although the difference in median survival was only 1.4 months (15.7 months v 14.3 months), the 5-year OS rate was 20.5% (95% CI, 14.2 to 29.8) with neoadjuvant chemoradiotherapy and 6.5% (95% CI, 3.1 to 13.7) with upfront surgery. The effect of neoadjuvant chemoradiotherapy was consistent across the prespecified subgroups, including resectable and borderline resectable pancreatic cancer.CONCLUSION: Neoadjuvant gemcitabine-based chemoradiotherapy followed by surgery and adjuvant gemcitabine improves OS compared with upfront surgery and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer.

Published
2022

14. External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer

Author

Versteijne, Eva, Suker, Mustafa, Groen, Jesse V., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Busch, Olivier R., De Hingh, Ignace H.J.T., De Jong, Koert P., Molenaar, I. Quintus, Van Santvoort, Hjalmar C., Verkooijen, Helena M., Van Eijck, Casper H., Van Tienhoven, Geertjan, Versteijne, Eva, Suker, Mustafa, Groen, Jesse V., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Busch, Olivier R., De Hingh, Ignace H.J.T., De Jong, Koert P., Molenaar, I. Quintus, Van Santvoort, Hjalmar C., Verkooijen, Helena M., Van Eijck, Casper H., and Van Tienhoven, Geertjan

Abstract

Objectives:To investigate the accrual proportion and patients' reasons for not participating in the PREOPANC trial on neoadjuvant chemoradiotherapy versus immediate surgery in resectable and borderline resectable pancreatic cancer, and to compare these patients' outcomes with those of patients who had been randomized in the trial.Summary of Background Data:The external validity of multicenter randomized trials in cancer treatment has been criticized for suboptimal non-representative inclusion. In trials, it is unclear how outcomes compare between randomized and nonrandomized patients.Methods:At 8 of 16 participant centers, this multicenter observational study identified validation patients, who had been eligible but not randomized during recruitment for the PREOPANC trial. We assessed the accrual proportion, investigated their most common reasons for not participating in the trial, and compared resection rates, radical (R0) resection rates, and overall survival between the validation patients and PREOPANC patients, who had been randomized in the trial to immediate surgery.Results:In total, 455 patients had been eligible during the recruitment period, 151 of whom (33%) had been randomized. Fifty-five percent of the 304 validation patients had refused to participate. Median overall survival in the validation group was 15.2 months, against 15.5 months in the PREOPANC group (P = 1.00). The respective resection rates (76% vs 73%) and R0 resection rates (51% vs 46%) did not differ between the groups.Conclusions:The PREOPANC trial included a reasonable percentage of 33% of eligible patients. In terms of the outcomes survival, resection rate, and R0 resection rate, this appeared to be a representative group.

Published
2022

15. High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma

Author

Aziz, Mohammad Hosein, van Dongen, Jelle C., Saida, Lawlaw, Suker, Mustafa, van Vugt, Jeroen L. A., van Putten, Yordi, Sideras, Kostandinos, Groen, Jesse V., Mieog, J. Sven D., Lucassen, Claudia J., Droop, Anneke, Mauff, Katya, Shahbazi Feshtali, Shirin, Groot Koerkamp, Bas, Mustafa, Dana A. M., van Eijck, Casper J., Aziz, Mohammad Hosein, van Dongen, Jelle C., Saida, Lawlaw, Suker, Mustafa, van Vugt, Jeroen L. A., van Putten, Yordi, Sideras, Kostandinos, Groen, Jesse V., Mieog, J. Sven D., Lucassen, Claudia J., Droop, Anneke, Mauff, Katya, Shahbazi Feshtali, Shirin, Groot Koerkamp, Bas, Mustafa, Dana A. M., and van Eijck, Casper J.

Abstract

Background and AimsFailing immune surveillance in pancreatic ductal adenocarcinoma (PDAC) is related to poor prognosis. PDAC is also characterized by its substantial alterations to patients' body composition. Therefore, we investigated associations between the host systemic immune inflammation response and body composition in patients with resected PDAC. MethodsPatients who underwent a pancreatectomy for PDAC between 2004 and 2016 in two tertiary referral centers were included. Skeletal muscle mass quantity and muscle attenuation, as well as subcutaneous and visceral adipose tissue at the time of diagnosis, were determined by CT imaging measured transversely at the third lumbar vertebra level. Baseline clinicopathological characteristics, laboratory values including the systemic immune inflammation index (SIII), postoperative, and survival outcomes were collected. ResultsA total of 415 patients were included, and low skeletal muscle mass quantity was found in 273 (65.7%) patients. Of the body composition indices, only low skeletal muscle mass quantity was independently associated with a high (>= 900) SIII (OR 7.37, 95% CI 2.31-23.5, p=0.001). The SIII was independently associated with disease-free survival (HR 1.86, 95% CI 1.12-3.04), and cancer-specific survival (HR 2.21, 95% CI 1.33-3.67). None of the body composition indices were associated with survival outcomes. ConclusionThis study showed a strong association between preoperative low skeletal muscle mass quantity and elevated host systemic immune inflammation in patients with resected PDAC. Understanding how systemic inflammation may contribute to changes in body composition or whether reversing these changes may affect the host systemic immune inflammation response could expose new therapeutic possibilities for improving patients' survival outcomes.

Published
2022

16. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial.

Author

van Dongen, Jelle C., Versteijne, Eva, Bonsing, Bert A., Mieog, J. Sven D., de Hingh, Ignace H.J.T., Festen, Sebastiaan, Patijn, Gijs A., van Dam, Ronald, van der Harst, Erwin, Wijsman, Jan H., Bosscha, Koop, van der Kolk, Marion, de Meijer, Vincent E., Liem, Mike S.L., Busch, Olivier R., Besselink, Marc G.H., van Tienhoven, Geertjan, Groot Koerkamp, Bas, van Eijck, Casper H.J., and Suker, Mustafa

Subjects
PANCREATIC cancer, CANCER chemotherapy, LAPAROSCOPY, PANCREATIC surgery, TUMOR classification, RANDOMIZED controlled trials, CANCER patients
Abstract

The necessity of the staging laparoscopy in patients with pancreatic cancer is still debated. The objective of this study was to assess the yield of staging laparoscopy for detecting occult metastases in patients with resectable or borderline resectable pancreatic cancer. This was a post-hoc analysis of the randomized controlled PREOPANC trial in which patients with resectable or borderline resectable pancreatic cancer were randomized between preoperative chemoradiotherapy or immediate surgery. Patients assigned to preoperative treatment underwent a staging laparoscopy prior to preoperative treatment according to protocol, to avoid unnecessary chemoradiotherapy in patients with occult metastatic disease. Of the 246 included patients, 7 did not undergo surgery. A staging laparoscopy was performed in 133 patients (55.6%) and explorative laparotomy in 106 patients (44.4%). At staging laparoscopy, occult metastases were detected in 13 patients (9.8%); 12 liver metastases and 1 peritoneal metastasis. At direct explorative laparotomy, occult metastases were found in 9 patients (8.5%); 6 with liver metastases, 1 with peritoneal metastases, and 2 with metastases at multiple sites. One patient had peritoneal metastases at exploration after a negative staging laparoscopy. Patients with occult metastases were more likely to receive palliative chemotherapy if found with staging laparoscopy compared to laparotomy (76.9% vs. 30.0%, p = 0.040). Staging laparoscopy detected occult metastases in about 10% of patients with resectable or borderline resectable pancreatic cancer. These patients were more likely to receive palliative systemic chemotherapy compared to patients in whom occult metastases were detected with laparotomy. A staging laparoscopy is recommended before planned resection. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma

Author

Aziz, Mohammad Hosein, primary, van Dongen, Jelle C., additional, Saida, Lawlaw, additional, Suker, Mustafa, additional, van Vugt, Jeroen L. A., additional, van Putten, Yordi, additional, Sideras, Kostandinos, additional, Groen, Jesse V., additional, Mieog, J. Sven D., additional, Lucassen, Claudia J., additional, Droop, Anneke, additional, Mauff, Katya, additional, Shahbazi Feshtali, Shirin, additional, Groot Koerkamp, Bas, additional, Mustafa, Dana A. M., additional, and van Eijck, Casper J., additional

Published
2022
Full Text
View/download PDF

19. External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer

Author

Versteijne, Eva, primary, Suker, Mustafa, additional, Groen, Jesse V., additional, Besselink, Marc G., additional, Bonsing, Bert A., additional, Bosscha, Koop, additional, Busch, Olivier R., additional, de Hingh, Ignace H. J. T., additional, de Jong, Koert P., additional, Molenaar, I. Quintus, additional, van Santvoort, Hjalmar C., additional, Verkooijen, Helena M., additional, Van Eijck, Casper H., additional, and van Tienhoven, Geertjan, additional

Published
2020
Full Text
View/download PDF

20. Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience

Author

Klaassen, Remy, primary, Steins, Anne, additional, Gurney‐Champion, Oliver J., additional, Bijlsma, Maarten F., additional, Tienhoven, Geertjan, additional, Engelbrecht, Marc R. W., additional, Eijck, Casper H. J., additional, Suker, Mustafa, additional, Wilmink, Johanna W., additional, Besselink, Marc G., additional, Busch, Olivier R., additional, Boer, Onno J., additional, Vijver, Marc J., additional, Hooijer, Gerrit K. J., additional, Verheij, Joanne, additional, Stoker, Jaap, additional, Nederveen, Aart J., additional, and Laarhoven, Hanneke W. M., additional

Published
2020
Full Text
View/download PDF

21. Patient Satisfaction and Quality of Life Before and After Treatment of Pancreatic and Periampullary Cancer: A Prospective Multicenter Study

Author

Mackay, Tara M., primary, van Rijssen, Lennart B., additional, Andriessen, Jurr O., additional, Suker, Mustafa, additional, Creemers, Geert-Jan, additional, Eskens, Ferry A., additional, de Hingh, Ignace H., additional, van de Poll-Franse, Lonneke V., additional, Sprangers, Mirjam A.G., additional, Busch, Olivier R., additional, Wilmink, Johanna W., additional, van Eijck, Casper H., additional, Besselink, Marc G., additional, van Laarhoven, Hanneke W., additional, and _, _, additional

Published
2020
Full Text
View/download PDF

24. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.

Author

Versteijne, Eva, van Dam, Jacob L, Suker, Mustafa, Janssen, Quisette P, Groothuis, Karin, Akkermans-Vogelaar, Janine M, Besselink, Marc G, Bonsing, Bert A, Buijsen, Jeroen, Busch, Olivier R, Creemers, Geert-Jan M, van Dam, Ronald M, Eskens, Ferry A L M, Festen, Sebastiaan, de Groot, Jan Willem B, Groot Koerkamp, Bas, de Hingh, Ignace H, Homs, Marjolein Y V, van Hooft, Jeanin E, and Kerver, Emile D

Published
2022
Full Text
View/download PDF

26. Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience

Author

Klaassen, R, Steins, A, Gurney-Champion, OJ, Bijlsma, MF, van Tienhoven, G, Engelbrecht, MRW, van Eijck, Casper, Suker, Mustafa, Wilmink, JW, Besselink, MGH, Busch, ORC, de Boer, OJ, de Vijver, MJV, Hooijer, G K J, Verheij, J, Stoker, J, Nederveen, AJ, van Laarhoven, HW, Klaassen, R, Steins, A, Gurney-Champion, OJ, Bijlsma, MF, van Tienhoven, G, Engelbrecht, MRW, van Eijck, Casper, Suker, Mustafa, Wilmink, JW, Besselink, MGH, Busch, ORC, de Boer, OJ, de Vijver, MJV, Hooijer, G K J, Verheij, J, Stoker, J, Nederveen, AJ, and van Laarhoven, HW

Published
2020

29. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial)

Author

Suker, Mustafa, primary, Nuyttens, Joost J., additional, Eskens, Ferry A.L.M., additional, Haberkorn, Brigitte C.M., additional, Coene, Peter-Paul L.O., additional, van der Harst, Erwin, additional, Bonsing, Bert A., additional, Vahrmeijer, Alexander L., additional, Mieog, J.Sven D., additional, Jan Swijnenburg, Rutger, additional, Roos, Daphne, additional, Koerkamp, B.Groot., additional, and van Eijck, Casper H.J., additional

Published
2019
Full Text
View/download PDF

31. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels

Author

Aziz, Mohammad Hosein, primary, Sideras, Kostandinos, additional, Aziz, Nasir Ahmad, additional, Mauff, Katya, additional, Haen, Roel, additional, Roos, Daphne, additional, Saida, Lawlaw, additional, Suker, Mustafa, additional, van der Harst, Erwin, additional, Mieog, Jan Sven, additional, Bonsing, Bert A., additional, Klaver, Yarne, additional, Koerkamp, Bas Groot, additional, and van Eijck, Casper H., additional

Published
2019
Full Text
View/download PDF

32. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis

Author

Janssen, Quisette P, primary, Buettner, Stefan, additional, Suker, Mustafa, additional, Beumer, Berend R, additional, Addeo, Pietro, additional, Bachellier, Philippe, additional, Bahary, Nathan, additional, Bekaii-Saab, Tanios, additional, Bali, Maria A, additional, Besselink, Marc G, additional, Boone, Brian A, additional, Chau, Ian, additional, Clarke, Stephen, additional, Dillhoff, Mary, additional, El-Rayes, Bassel F, additional, Frakes, Jessica M, additional, Grose, Derek, additional, Hosein, Peter J, additional, Jamieson, Nigel B, additional, Javed, Ammar A, additional, Khan, Khurum, additional, Kim, Kyu-Pyo, additional, Kim, Song Cheol, additional, Kim, Sunhee S, additional, Ko, Andrew H, additional, Lacy, Jill, additional, Margonis, Georgios A, additional, McCarter, Martin D, additional, McKay, Colin J, additional, Mellon, Eric A, additional, Moorcraft, Sing Yu, additional, Okada, Ken-Ichi, additional, Paniccia, Alessandro, additional, Parikh, Parag J, additional, Peters, Niek A, additional, Rabl, Hans, additional, Samra, Jaswinder, additional, Tinchon, Christoph, additional, van Tienhoven, Geertjan, additional, van Veldhuisen, Eran, additional, Wang-Gillam, Andrea, additional, Weiss, Matthew J, additional, Wilmink, Johanna W, additional, Yamaue, Hiroki, additional, Homs, Marjolein Y V, additional, van Eijck, Casper H J, additional, Katz, Matthew H G, additional, and Groot Koerkamp, Bas, additional

Published
2019
Full Text
View/download PDF

34. Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD) A Multicenter Patient-blinded Randomized Controlled Trial

Author

Cancer, MS CGO, de Rooij, Thijs, van Hilst, Jony, van Santvoort, Hjalmar, Boerma, Djamila, van den Boezem, Peter, Daams, Freek, van Dam, Ronald, Dejong, Cees, van Duyn, Eino, Dijkgraaf, Marcel, van Eijck, Casper, Festen, Sebastiaan, Gerhards, Michael, Koerkamp, Bas Groot, de Hingh, Ignace, Kazemier, Geert, Klaase, Joost, de Kleine, Ruben, van Laarhoven, Cornelis, Luyer, Misha, Patijn, Gijs, Steenvoorde, Pascal, Suker, Mustafa, Abu Hilal, Moh'd, Busch, Olivier, Besselink, Marc, Cancer, MS CGO, de Rooij, Thijs, van Hilst, Jony, van Santvoort, Hjalmar, Boerma, Djamila, van den Boezem, Peter, Daams, Freek, van Dam, Ronald, Dejong, Cees, van Duyn, Eino, Dijkgraaf, Marcel, van Eijck, Casper, Festen, Sebastiaan, Gerhards, Michael, Koerkamp, Bas Groot, de Hingh, Ignace, Kazemier, Geert, Klaase, Joost, de Kleine, Ruben, van Laarhoven, Cornelis, Luyer, Misha, Patijn, Gijs, Steenvoorde, Pascal, Suker, Mustafa, Abu Hilal, Moh'd, Busch, Olivier, and Besselink, Marc

Published
2019

35. Monitoring the microcirculation

Author

Suker, Mustafa, Ince, Can, Translational Physiology, and ACS - Microcirculation

Abstract

This chapter reviews the possibilities for monitoring the microcirculation. Techniques and parameters are described. Microcirculatory monitoring can be used in the perioperative setting to assess goal-directed fluid therapy. The chapter ends with a case report.

Published
2018

37. Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD)

Author

de Rooij, Thijs, primary, van Hilst, Jony, additional, van Santvoort, Hjalmar, additional, Boerma, Djamila, additional, van den Boezem, Peter, additional, Daams, Freek, additional, van Dam, Ronald, additional, Dejong, Cees, additional, van Duyn, Eino, additional, Dijkgraaf, Marcel, additional, van Eijck, Casper, additional, Festen, Sebastiaan, additional, Gerhards, Michael, additional, Groot Koerkamp, Bas, additional, de Hingh, Ignace, additional, Kazemier, Geert, additional, Klaase, Joost, additional, de Kleine, Ruben, additional, van Laarhoven, Cornelis, additional, Luyer, Misha, additional, Patijn, Gijs, additional, Steenvoorde, Pascal, additional, Suker, Mustafa, additional, Abu Hilal, Moh’d, additional, Busch, Olivier, additional, and Besselink, Marc, additional

Published
2019
Full Text
View/download PDF

38. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.

Author

Versteijne, Eva, Suker, Mustafa, Groothuis, Karin, Akkermans-Vogelaar, Janine M., Besselink, Marc G., Bonsing, Bert A., Buijsen, Jeroen, Busch, Olivier R., Creemers, Geert-Jan M., van Dam, Ronald M., Eskens, Ferry A.L.M., Festen, Sebastiaan, de Groot, Jan Willem B., Groot Koerkamp, Bas, de Hingh, Ignace H., Homs, Marjolein Y.V., van Hooft, Jeanin E., Kerver, Emile D., Luelmo, Saskia A.C., and Neelis, Karen J.

Published
2020
Full Text
View/download PDF

40. Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.

Author

Janssen, Quisette, primary, Buettner, Stefan, additional, Suker, Mustafa, additional, Margonis, Georgios A, additional, Paniccia, Alessandro, additional, El-Rayes, Bassel F., additional, Bahary, Nathan, additional, Chau, Ian, additional, Hosein, Peter Joel, additional, Ko, Andrew H., additional, Lacy, Jill, additional, Jamieson, Nigel, additional, Tinchon, Christoph, additional, Kim, Kyu-Pyo, additional, Besselink, Marc G., additional, Wilmink, Johanna, additional, Homs, Marjolein Y.V., additional, van Eijck, Casper H.J., additional, Katz, Matthew H. G., additional, and Groot Koerkamp, Bas, additional

Published
2018
Full Text
View/download PDF

41. The Dutch Pancreas Biobank Within the Parelsnoer Institute

Author

Strijker, Marin, primary, Gerritsen, Arja, additional, van Hilst, Jony, additional, Bijlsma, Maarten F., additional, Bonsing, Bert A., additional, Brosens, Lodewijk A., additional, Bruno, Marco J., additional, van Dam, Ronald M., additional, Dijk, Frederike, additional, van Eijck, Casper H., additional, Farina Sarasqueta, Arantza, additional, Fockens, Paul, additional, Gerhards, Michael F., additional, Groot Koerkamp, Bas, additional, van der Harst, Erwin, additional, de Hingh, Ignace H., additional, van Hooft, Jeanin E., additional, Huysentruyt, Clément J., additional, Kazemier, Geert, additional, Klaase, Joost M., additional, van Laarhoven, Cornelis J., additional, van Laarhoven, Hanneke W., additional, Liem, Mike S., additional, de Meijer, Vincent E., additional, van Rijssen, L. Bengt, additional, van Santvoort, Hjalmar C., additional, Suker, Mustafa, additional, Verhagen, Judith H., additional, Verheij, Joanne, additional, Verspaget, Hein W., additional, Wennink, Roos A., additional, Wilmink, Johanna W., additional, Molenaar, I. Quintus, additional, Boermeester, Marja A., additional, Busch, Olivier R., additional, and Besselink, Marc G., additional

Published
2018
Full Text
View/download PDF

42. The Dutch Pancreas Biobank within the Parelsnoer Institute : A nationwide Biobank of pancreatic and periampullary diseases

Author

Strijker, Marin, Gerritsen, Arja, Van Hilst, Jony, Bijlsma, Maarten F., Bonsing, Bert A., Brosens, Lodewijk A., Bruno, Marco J., Van Dam, Ronald M., Dijk, Frederike, Van Eijck, Casper H., Farina Sarasqueta, Arantza, Fockens, Paul, Gerhards, Michael F., Groot Koerkamp, Bas, Van Der Harst, Erwin, De Hingh, Ignace H., Van Hooft, Jeanin E., Huysentruyt, Clément J., Kazemier, Geert, Klaase, Joost M., Van Laarhoven, Cornelis J., Van Laarhoven, Hanneke W., Liem, Mike S., De Meijer, Vincent E., Van Rijssen, L. Bengt, Van Santvoort, Hjalmar C., Suker, Mustafa, Verhagen, Judith H., Verheij, Joanne, Verspaget, Hein W., Wennink, Roos A., Wilmink, Johanna W., Molenaar, I. Quintus, Boermeester, Marja A., Busch, Olivier R., Besselink, Marc G., Strijker, Marin, Gerritsen, Arja, Van Hilst, Jony, Bijlsma, Maarten F., Bonsing, Bert A., Brosens, Lodewijk A., Bruno, Marco J., Van Dam, Ronald M., Dijk, Frederike, Van Eijck, Casper H., Farina Sarasqueta, Arantza, Fockens, Paul, Gerhards, Michael F., Groot Koerkamp, Bas, Van Der Harst, Erwin, De Hingh, Ignace H., Van Hooft, Jeanin E., Huysentruyt, Clément J., Kazemier, Geert, Klaase, Joost M., Van Laarhoven, Cornelis J., Van Laarhoven, Hanneke W., Liem, Mike S., De Meijer, Vincent E., Van Rijssen, L. Bengt, Van Santvoort, Hjalmar C., Suker, Mustafa, Verhagen, Judith H., Verheij, Joanne, Verspaget, Hein W., Wennink, Roos A., Wilmink, Johanna W., Molenaar, I. Quintus, Boermeester, Marja A., Busch, Olivier R., and Besselink, Marc G.

Published
2018

43. The Dutch Pancreas Biobank within the Parelsnoer Institute: A nationwide Biobank of pancreatic and periampullary diseases

Author

MS CGO, Pathologie Groep Bovenschen, Pathologie Pathologen staf, Cancer, Oogheelkunde Onderzoek, Strijker, Marin, Gerritsen, Arja, Van Hilst, Jony, Bijlsma, Maarten F., Bonsing, Bert A., Brosens, Lodewijk A., Bruno, Marco J., Van Dam, Ronald M., Dijk, Frederike, Van Eijck, Casper H., Farina Sarasqueta, Arantza, Fockens, Paul, Gerhards, Michael F., Groot Koerkamp, Bas, Van Der Harst, Erwin, De Hingh, Ignace H., Van Hooft, Jeanin E., Huysentruyt, Clément J., Kazemier, Geert, Klaase, Joost M., Van Laarhoven, Cornelis J., Van Laarhoven, Hanneke W., Liem, Mike S., De Meijer, Vincent E., Van Rijssen, L. Bengt, Van Santvoort, Hjalmar C., Suker, Mustafa, Verhagen, Judith H., Verheij, Joanne, Verspaget, Hein W., Wennink, Roos A., Wilmink, Johanna W., Molenaar, I. Quintus, Boermeester, Marja A., Busch, Olivier R., Besselink, Marc G., MS CGO, Pathologie Groep Bovenschen, Pathologie Pathologen staf, Cancer, Oogheelkunde Onderzoek, Strijker, Marin, Gerritsen, Arja, Van Hilst, Jony, Bijlsma, Maarten F., Bonsing, Bert A., Brosens, Lodewijk A., Bruno, Marco J., Van Dam, Ronald M., Dijk, Frederike, Van Eijck, Casper H., Farina Sarasqueta, Arantza, Fockens, Paul, Gerhards, Michael F., Groot Koerkamp, Bas, Van Der Harst, Erwin, De Hingh, Ignace H., Van Hooft, Jeanin E., Huysentruyt, Clément J., Kazemier, Geert, Klaase, Joost M., Van Laarhoven, Cornelis J., Van Laarhoven, Hanneke W., Liem, Mike S., De Meijer, Vincent E., Van Rijssen, L. Bengt, Van Santvoort, Hjalmar C., Suker, Mustafa, Verhagen, Judith H., Verheij, Joanne, Verspaget, Hein W., Wennink, Roos A., Wilmink, Johanna W., Molenaar, I. Quintus, Boermeester, Marja A., Busch, Olivier R., and Besselink, Marc G.

Published
2018

44. Patients with chronic mesenteric ischemia have an altered sublingual microcirculation

Author

Harki, Jihan, Suker, Mustafa, Tovar-Doncel, MS, van Dijk, Louisa, Leemreis - van Noord, Désirée, van Eijck, Casper, Bruno, Marco, Kuipers, Ernst, Ince, Can, Harki, Jihan, Suker, Mustafa, Tovar-Doncel, MS, van Dijk, Louisa, Leemreis - van Noord, Désirée, van Eijck, Casper, Bruno, Marco, Kuipers, Ernst, and Ince, Can

Published
2018

45. Patients with chronic mesenteric ischemia have an altered sublingual microcirculation

Author

Harki,Jihan, Suker,Mustafa, Tovar-Doncel,M Sherezade, van Dijk,Louisa, van Noord,Désirée, van Eijck,Casper, Bruno,Marco, Kuipers,Ernst, Ince,Can, Harki,Jihan, Suker,Mustafa, Tovar-Doncel,M Sherezade, van Dijk,Louisa, van Noord,Désirée, van Eijck,Casper, Bruno,Marco, Kuipers,Ernst, and Ince,Can

Abstract

Jihan Harki,1,* Mustafa Suker,2,* M Sherezade Tovar-Doncel,3 Louisa JD van Dijk,1 Désirée van Noord,1 Casper HJ van Eijck,2 Marco J Bruno,1 Ernst J Kuipers,1,4 Can Ince5 1Department of Gastroenterology and Hepatology, 2Department of Surgery, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands; 3Department of Anesthesiology, University Hospital Rio Hortega, Valladolid, Spain; 4Department of Internal Medicine, 5Department of Intensive Care, Erasmus MC University Medical Center, Rotterdam, the Netherlands *These authors contributed equally to this work Background: Little is known about the microcirculatory alterations in patients with chronic mesenteric ischemia (CMI). We hypothesized that patients with CMI have an impaired microcirculatory function and show an oral microcirculatory response after caloric challenge compared to healthy controls.Methods: All patients and controls received the standard workup for CMI. Sublingual microcirculation was evaluated before (T0) and 20 minutes after (T1) feeding. The total vessel density (TVD; mm/mm2), perfused vessel density (PVD; mm/mm2), proportion of perfused vessels (PPV; %) and microvascular flow index (MFI; AU) were assessed.Results: We included 12 patients (63.2 years [IQR 48.8–70.4 years], 67% males) and 12 controls (32.7 years [IQR 27.7–38.1 years], 42% males). At baseline, patients with CMI had a decreased PPV of the sublingual small vessels (median 84.8% vs 95.7%, P=0.006), PPV of all vessels (PPV median 85.4% vs 95.3%, P=0.007) and microvascular flow index of all vessels (MFIa; median 3.00 vs 2.80, P=0.039) compared to healthy controls. After caloric challenge, PVD increased significantly in both small vessels (perfused vessel density of the small vessels [PVDs]) and all vessels (perfused vessel density of all vessels [PVDa]; PVDs [T0]) median 16.3 [IQR 13.3–22.1] vs [T1] median 19.9 [IQR 14.2–26.2], P=0.008; PVDa [T0] median 19.1 [I

Published
2018

46. Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing cancer surgery of the alimentary tract

Author

van Vugt, Jeroen L. A., primary, Buettner, Stefan, additional, Levolger, Stef, additional, Coebergh van den Braak, Robert R. J., additional, Suker, Mustafa, additional, Gaspersz, Marcia P., additional, de Bruin, Ron W. F., additional, Verhoef, Cornelis, additional, van Eijck, Casper H. C., additional, Bossche, Niek, additional, Groot Koerkamp, Bas, additional, and IJzermans, Jan N. M., additional

Published
2017
Full Text
View/download PDF

49. Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection.

Author

Vietsch, Eveline E., Peran, Ivana, Suker, Mustafa, van den Bosch, Thierry P. P., van der Sijde, Fleur, Kros, Johan M., van Eijck, Casper H. J., and Wellstein, Anton

Subjects
RAS oncogenes, PANCREATIC cancer, PROGRESSION-free survival, CANCER patients, B cells, IN situ hybridization, CANCER invasiveness, TUMORS
Abstract

Featured Application: Circulating prognostic biomarker in pancreatic cancer. Clinical follow-up aided by changes in the expression of circulating microRNAs (miRs) may improve prognostication of pancreatic ductal adenocarcinoma (PDAC) patients. Changes in 179 circulating miRs due to cancer progression in the transgenic KrasG12D/+; Trp53R172H/+; P48-Cre (KPC) animal model of PDAC were analyzed for serum miRs that are altered in metastatic disease. In addition, expression levels of 250 miRs were profiled before and after pancreaticoduodenectomy in the serum of two patients with resectable PDAC with different progression free survival (PFS) and analyzed for changes indicative of PDAC recurrence after resection. Three miRs that were upregulated ≥3-fold in progressive PDAC in both mice and patients were selected for validation in 26 additional PDAC patients before and after resection. We found that high serum miR-125b-5p and miR-99a-5p levels after resection are significantly associated with shorter PFS (HR 1.34 and HR 1.73 respectively). In situ hybridization for miR detection in the paired resected human PDAC tissues showed that miR-125b-5p and miR-99a-5p are highly expressed in inflammatory cells in the tumor stroma, located in clusters of CD79A expressing cells of the B-lymphocyte lineage. In conclusion, we found that circulating miR-125b-5p and miR-99a-5p are potential immune-cell related prognostic biomarkers in PDAC patients after surgery. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

50. Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing cancer surgery of the alimentary tract

Author

van Vugt, Jeroen, Buttner, Stefan, Levolger, S, van den Braak, R, Suker, Mustafa, Gaspersz, Marcia, de Bruin, Ron, Verhoef, Kees, van Eijck, CHC, Bossche, N, Groot Koerkamp, B, IJzermans, J.N.M., van Vugt, Jeroen, Buttner, Stefan, Levolger, S, van den Braak, R, Suker, Mustafa, Gaspersz, Marcia, de Bruin, Ron, Verhoef, Kees, van Eijck, CHC, Bossche, N, Groot Koerkamp, B, and IJzermans, J.N.M.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results